Astria Therapeutics (ATXS) just unveiled an announcement.
Astria Therapeutics, Inc. conducted its Annual Meeting of Stockholders on June 5, 2024, where shareholders made pivotal decisions on the company’s future. They approved an expansion of the stock incentive plan, increasing shares by 5,750,000 and extending it for ten years. Additionally, three Class III directors were elected to the board, Ernst & Young LLP was ratified as the accounting firm for the upcoming fiscal year, and the executive compensation plan received advisory approval. These outcomes reflect shareholder confidence in Astria’s strategic direction and governance.
For a thorough assessment of ATXS stock, go to TipRanks’ Stock Analysis page.
